New stem cell transplant option for patients without a perfect donor match

NCT ID NCT02356653

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This expanded access program offers a stem cell transplant using donor cells that have been specially processed to remove certain immune cells, reducing the risk of graft-versus-host disease. It is for patients with serious blood disorders, immune deficiencies, or metabolic diseases who lack a fully matched sibling donor and cannot join other clinical trials. Up to 100 participants will receive the transplant, and researchers will track survival, graft success, and complications.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

Donor stem cells with T-cell depletion (CliniMACs)

What this could lead to

If successful, this approach could provide a treatment option for patients with life-threatening blood or immune disorders who lack a fully matched donor.

What could go wrong

This is an early-phase expanded access protocol, not a controlled trial. Risks include graft failure, graft-versus-host disease, and infection. Results may not apply broadly.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LEUKEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute leukemia Bone Marrow Failure Disorders bone marrow failure syndrome chronic leukemia hemoglobinopathy immune dysregulation-polyendocrinopathy-enteropathy-X-linked syndrome immunodeficiency disease inborn error of immunity inborn errors of metabolism leukemia lymphoma myelodysplastic syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Children's Hospital of Philadelphia

    RECRUITING

    Philadelphia, Pennsylvania, 19104, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

    Contact